Chenglong Han - Concepedia

Author

Chenglong Han

Also Known As

C Han, C. Han, CHENGLONG HAN, Chaolu Han, Chenglong Han, Chirstopher Han, Chunxin Han, Han, C, Han, C.L., Han, Chenglong

191

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)University of California San Diego Medical University of Vienna University of Pennsylvania Icahn School of Medicine at Mount Sinai

About

Chenglong Han is an author at Janssen (United States) specializing in medicine, clinical trials, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	408
2	Health Sciences	1	1	13
3	Public Health	1	1	10
4	Social Sciences	1	1	10
5	Diagnostic Sciences	1	1	13

Chenglong Han

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Chenglong Han, Don Robinson, Monica Hackett, PubMed	2006	720
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study Josef S Smolen, Chenglong Han, M Bala, Arthritis & Rheumatism	2005	455
Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial Josef S Smolen, Désirée van der Heijde, E. William St. Clair, Arthritis & Rheumatism	2006	433
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial Richard G. Langley, Steven R. Feldman, Chenglong Han, Journal of the American Academy of Dermatology PsychoneuroimmunologyPsychiatrySystemic TreatmentClinical TrialsDepression	2010	213
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study William J. Sandborn, Geert D’Haens, Walter Reinisch, Gastroenterology	2022	188
Infliximab Improves Quality of Life in Patients with Crohn's Disease Gary R. Lichtenstein, Mohan Bala, Chenglong Han, Inflammatory Bowel Diseases	2002	161
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study Atul Deodhar, Jürgen Braun, Robert D. Inman, Annals of the Rheumatic Diseases	2014	141
Infliximab treatment maintains employability in patients with early rheumatoid arthritis Josef S Smolen, Chenglong Han, Désirée van der Heijde, Arthritis & Rheumatism	2006	111
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial Mark Lebwohl, Kim Papp, Chenglong Han, British Journal of Dermatology	2009	96
Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study Kenneth B. Gordon, April W. Armstrong, Chenglong Han, Journal of the European Academy of Dermatology and Venereology	2018	92

Page 1